Colorectal cancer (CRC) is a cause of high morbidity and mortality worldwide. The incidence of CRC in Saudi Arabia is rising despite significant advances in the management of CRC. According to the Saudi Cancer Registry, it is the most common cancer in males across all ages in Saudi Arabia ([@bib4]). Identification of a new targeted therapy that allows progress in the management of CRC and improves survival is warranted.

Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that was first identified as part of chromosomal rearrangement as a fusion partner of nucleophosmin ([@bib43]). Other fusion partners to ALK such as *KIF5B* ([@bib58]), *NPM1* ([@bib43]), *RET* ([@bib60]), *ROS* ([@bib60]), *VCL* ([@bib18]) and *TFG* ([@bib27]) genes have also been described. The products of these fusion proteins have lead to constitutively activated ALK tyrosine kinase ([@bib43]; [@bib25]; [@bib27]; [@bib36]; [@bib38]; [@bib12]; [@bib17]; [@bib19]; [@bib22]; [@bib37]; [@bib41]; [@bib5]; [@bib54]; [@bib18]; [@bib59]). Furthermore, many recent reports have shown that the ALK kinase is constitutively activated by additional mechanisms such as activating mutations ([@bib15]; [@bib23]; [@bib28]) and *ALK* gene amplification ([@bib51]; [@bib62]; [@bib63]).

The discovery of *ALK* gene dysregulation and its potential utility as a biomarker in many solid tumours such as inflammatory myofibroblastic tumours ([@bib25]; [@bib46]), oesophageal squamous cell carcinoma ([@bib29]; [@bib21]), breast carcinoma ([@bib62]), lung adenocarcinoma ([@bib51]; [@bib60]), paediatric renal cell carcinoma ([@bib18]) and ovarian cancer ([@bib29]; [@bib21]) have led to the development of ALK inhibitors with promising results in preclinical models and early clinical trials ([@bib46]; [@bib16]; [@bib32]; [@bib26]; [@bib35]; [@bib55]; [@bib62]). Two recent studies have detected EML4 and C2orf44 as fusion partners of ALK in CRC ([@bib39]; [@bib40]). This has prompted us to study the potential role of *ALK* gene alterations in a very large cohort of CRC in Saudi Arabian patients. In addition, mutations in KRAS and BRAF are known to influence response to treatment. Therefore, an attempt was also made to investigate the microsatellite instability (MSI) and mutational status of these genes to study their correlation with ALK alterations in CRC.

In this work, we sought to perform detailed analysis of *ALK* gene copy number, rearrangement and mutation, as well as expression pattern of ALK. We then correlated ALK alterations with clinical data including survival analysis, pathological parameters and key molecular alterations in CRC.

Materials and Methods
=====================

Patients selection and TMA construction
---------------------------------------

A total of 770 patients with CRC diagnosed between 1990 and 2011 were randomly selected from King Faisal Specialist Hospital and Research Centre (KFSHRC) and Security Forces Hospital, Riyadh. A colorectal progression tissue microarray (TMA) that represents the entire spectrum of lesions in colorectal carcinogenesis was constructed comprising 770 CRC samples, 229 adjacent normal colorectal mucosa, 24 adenoma and 47 lymph node metastasis as described previously ([@bib6]). Clinical and histopathological data were available for all these patients. Patients with colon cancer underwent surgical colonic resection and those with rectal cancer underwent anterior resection or abdominoperineal resection. All node-positive colon cancers received 5-fluorouracil-based adjuvant chemotherapy. A vast majority of the rectal cancers received radiotherapy alone or chemoradiotherapy before surgery, followed by adjuvant chemotherapy after surgery. Colorectal Unit, Department of Surgery (KFSHRC and Security Forces Hospital), provided long-term follow-up data about the date and cause of death for this cohort of patients. Follow-up was calculated from the date of resection of the primary tumour, and all surviving cases were censored for survival analysis on 31 December 2011. Two pathologists (PB and SP) reviewed all tumours for grade and histological subtype. The institutional review board of the KFSHRC approved the study.

ALK expression analysis (immunohistochemistry)
----------------------------------------------

As described earlier, TMA slides were processed and stained manually ([@bib8]). Primary ALK antibody (clone D5F3; CST; 1 : 100 dilution; Dako Target Retrieval, pH 9) was applied and incubated overnight. Antigen--antibody reaction was visualised by an enhanced polymer-based detection system, Envision Plus dual-link System-HRP, for 1 h. Diaminobenzidene (DAB+ Dako, Glostrup, Denmark) was used for 5 min as the chromogen. The positive control was from a known CD30-positive ALCL case. The negative control was a mouse immunoglobulin G1 serum substitution for the primary antibody (ALK). Earlier reports have shown that ALK protein expression is always lower in ALK-rearranged lung adenocarcinomas (1 : 100) relative to ALK-rearranged ALCLs (1 : 1000). ([@bib42]). Taking into consideration the limitation of using ALCL as a positive control because of high concentration of ALK protein epitopes as compared with solid tumours, we used a lower dilution of the ALK antibody (1 : 100) to ensure optimal detection of low concentration of the ALK protein in CRC.

Two pathologists (PB and SP) performed immunohistochemistry (IHC) scoring to determine a H score as reported earlier ([@bib61]), and consensus was established by reviewing the slides together in the case of discrepant scores. A final H score (range 0--300) was obtained by adding the sum of scores obtained for each intensity and proportion of area stained ([@bib1]). X-tile plots were constructed for assessment of biomarker and optimisation of cutoff points based on outcome as has been described earlier ([@bib13]). Colorectal cancers were grouped into two groups based on X-tile plots: one with complete absence (H score=0)and the other group with ALK expression (H score \>0), depending on the H score.

Fluorescence *in situ* hybridisation
------------------------------------

Fluorescence *in situ* hybridization (FISH) assay for *ALK* gene rearrangement and amplification was performed on a TMA ([@bib7]). Bacterial artificial chromosome (BAC) corresponding to *ALK* gene was utilised to analyse copy number variation. The BAC clone was selected by browsing Ensembl Genome Browser <http://ensembl.org/>. Bacterial artificial chromosome RP11--328L16 corresponding to the *ALK* gene were purchased from Children\'s Hospital Oakland Research Institute (Oakland, CA, USA). The BAC clone was cultured, DNA was isolated and labelled with Digoxygenin using the DNA labelling kit from Roche (Hamburg, Germany). A commercially available centromeric probe for chromosome2 CEP2 (Abbott Molecular, Des Plaines, IL, USA) was utilised as an internal control. Centromere 2 was selected as a reference gene to rule out polyploidy based on earlier reports, which indicate that background numeric aberrations affecting chromosome 2 in CRC are very rare ([@bib50]; [@bib14]; [@bib9]). Fluorescence *in situ* hybridization on CRC TMA was performed as previously described ([@bib30]). Tissue samples were classified with an ALK/centromere 2 ratio of 1.0 as normal; between 1.0 and 2.0 as having ALK gains; and 2.5 and above as amplified ([@bib51]). A minimum of 50 cells were scored for the presence of both centromeric and ALK signals.

Fluorescence *in situ* hybridisation assay for the *ALK* gene rearrangement was performed on the CRC TMA slides with the use of an ALK break-apart probe set obtained from Vysis LSI ALK Dual break-apart rearrangement probe (Abbott Molecular). The slides were pre-processed with a paraffin pre-treatment reagent kit. The FISH assays were performed according to the manufacturer\'s instructions. The occurrence of an ALK rearrangement (ALK FISH positive) was concluded if \>15% of tumour cells showed split red and green signals and/or single red signals in addition to a single-fused signal; otherwise, the specimen was classified as ALK FISH negative ([@bib34]). A positive and negative slide for rearrangement available from Vysis (Abbott Molecular) were used as controls. Increase in the number of fused signals were considered to be amplifications and gains. A minimum of 50 cells per sample were scored for ALK rearrangement.

DNA isolation
-------------

DNA was extracted from paraffin-embedded CRC tissues using Gentra DNA isolation kit (Gentra, Minneapolis, MN, USA) following the manufacturer\'s recommendations as described previously ([@bib2]).

Quantitative real-time PCR
--------------------------

Further confirmation of FISH results were done by quantitative PCR (qPCR). DNA from formalin-fixed, paraffin-embedded samples of colon cancer with normal and increased ALK copy number by FISH were selected for validation by quantitative real-time (qRT) PCR. DNA content was normalised to that of long interspersed elements (LINE1), a repetitive element for which copy number per haploid genome is similar in both the normal DNA sample and DNA from cancer cells. Primers were designed by Primer express 3.0 software (Applied Biosystems, Foster City, CA, USA) to hybridise to sequences of genomic DNA for ALK. The primers to the genomic sequences were ALK and LINE1, and are provided in [Supplementary Table 1](#sup1){ref-type="supplementary-material"} ([@bib31]). The PCR conditions and Light Cycler PCR protocol were as previously described ([@bib1]). The Pfaffle method for relative quantification was used to calculate the fold change for colon cancer samples that showed normal copy number and amplification of *ALK* gene ([@bib48]). The relative copy number ratio of a target gene is calculated based on the efficiency and crossing point deviation of samples (normal) *vs* colon cancer, and is expressed in comparison with a reference gene (*LINE1*). For a normal cell, the copy number of a gene per haploid genome should be 1.

PCR and DNA sequencing for *ALK*, *KRAS* and *BRAF* gene
--------------------------------------------------------

ALK mutational analysis was performed on 101 CRC samples that have high expression of ALK protein by IHC. Primer express 3.0 software (Applied Biosystems) was used to design the primers for exons of tyrosine kinase domain (exons 20--28) and their flanking intronic sequences of *ALK* gene ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}); exon 1 of BRAF; exons 1 and 2 of KRAS ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). The PCR sequencing protocol for ALK was same as described with minor change in the annealing temperature being 60 °C for 45 s ([@bib1]). The samples were finally analysed on an ABI PRISM 3100 × l genetic analyzer (Applied Biosystems).

Microsatellite markers and analyses
-----------------------------------

Allelic imbalances were measured by performing microsatellite analysis on all matched normal and tumour tissue by PCR amplification. A reference panel of five pairs of microsatellite primers comprising two mononucleotide microsatellites (BAT25 and BAT26) and three dinucleotide microsatellites (DS123, D5S346 and D17S250) were used to determine tumour MSI status ([@bib11]). Multiplex PCR was performed in a total volume of 25 *μ*l using 50 ng of genomic DNA, 2.5 *μ*l 10 × Taq buffer, 1.5 *μ*l MgCl~2~ (25 m[M]{.smallcaps}), 10 pmol of fluorescent-labelled primers, 0.05 *μ*l dNTP (10 m[M]{.smallcaps}) and 0.2 *μ*l Taq polymerase (1 U *μ*l^−1^; all reagents were obtained from Qiagen Inc., Valencia, CA, USA). PCR was performed using an MJ Research PTC-200 thermocycler (Bruno, QC, Canada).

Statistical analysis
--------------------

The JMP 9.0 (SAS Institute Inc., Cary, NC, USA) software package was used for data analyses. Survival curves were generated using the Kaplan--Meier method, with significance evaluated using the Mantel--Cox log-rank test. Risk ratio was calculated using the Cox proportional hazard model in both univariate and multivariate analyses. The values of *P*\<0.05 were considered statistically significant.

Results
=======

Clinico-pathological data
-------------------------

The characteristics of the 770 CRC patients are summarised in [Table 1](#tbl1){ref-type="table"}. The median age at the time of surgery was 57 years (interquartile range (IQR) 47.7--68.0 years). The median length of follow-up available for surviving patients was 43.0 months (IQR 20--65 months). The overall median 5-year overall survival for the study population was 35 months (IQR 15--60 months).

ALK protein expression by IHC
-----------------------------

One hundred and three cases out of 703 representative cases were positive by IHC, representing 14.6% of all cases studied by IHC. Anaplastic lymphoma kinase IHC expression was non-informative in 67 (8.7%) TMA spots mainly because of the loss of tissue core during processing of the slide or because of the TMA spot being non-representative of tumour. The staining pattern ranged from an intense 3+ staining in the cytoplasm and/or membrane ([Figure 1A and B](#fig1){ref-type="fig"}) to 2+ moderate cytoplasmic staining and 1+ faint cytoplasmic staining ([Figure 1--E](#fig1){ref-type="fig"}). A small subset of CRC tumours showed punctate coarse granular cytoplasmic staining seen in 1.4% (10 out of 703) of the CRC spots and was observed in 20--100% of the tumour cells in each spot. Anaplastic lymphoma kinase expression was not observed in the 300 normal colorectal mucosa. However, 29.2% (7 out of 24) of adenomas analysed showed ALK expression, thereby indicating that altered ALK expression is a potential early event in colorectal carcinogenesis.

ALK copy number alterations and translocations
----------------------------------------------

In our series of 770 CRC samples, 756 were analysable by FISH utilising the BAC probe RP11--328L16, as well as the ALK rearrangement probe. Fourteen TMA spots (1.8%) were non-representative either because of lack of tumour or absence of tissue spot. Of the spots analysed, 20 cases (2.6%) showed amplification of *ALK* gene ([Figure 2A and C](#fig2){ref-type="fig"}). No high level amplification of *ALK* gene was observed in these 20 samples. We found ALK copy number gains in six (0.8%) cases and none of them showed polysomy. In the majority of these cases, gains in *ALK* gene were seen in at least 30% of the tumour cells. Colorectal cancer cases with either amplification or gain in *ALK* gene were combined in one subgroup and referred to ALK amplification/gain. [Table 2](#tbl2){ref-type="table"} lists the clinico-pathological correlation of these CRC patients with ALK amplification/gain. We did not observe any *ALK* gene amplification or gain in copy number in colorectal adenomas or normal colorectal mucosa. The FISH findings were further confirmed by qPCR analysis on a few selected amplified and non-amplified CRC samples ([Figure 2E](#fig2){ref-type="fig"}). We investigated the presence of EML4 fusion with ALK and found no translocation of these two genes. Analysis of other uncommon fusion genes such as TFG and KIF5B, which have been previously reported in lung cancer, were not investigated ([@bib53]; [@bib58]).

Correlation of *ALK* gene copy number alteration and clinico-pathological features
----------------------------------------------------------------------------------

The number of cases that were overlapping with FISH and immunohistochemical analysis for *ALK* gene was 697, that is, data were available for both IHC and FISH in 697 TMA spots. Although *ALK* gene amplification did not correlate with ALK protein expression in all CRC samples (*P*=0.8130), a good concordance was observed between *ALK* gene copy number and ALK expression (*P*=0.0246) in advanced CRC subgroup: Stage III--IV CRC subgroup. In addition, *ALK* gene amplification alone was significantly associated with poor tumour differentiation ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}) in advanced CRC subgroup: Stage IV (*P*=0.0233). However, there were only three samples in Stage IV CRC subgroup that showed ALK amplification/gain in advanced CRC subgroup: Stage IV. In all CRC samples, ALK amplification and ALK gain did not show any association with age (*P*=0.5003), gender (*P*=0.8368), histology subtype (*P*=0.1792), tumour grade (*P*=0.3142) and stage (*P*=0.7904; [Table 2](#tbl2){ref-type="table"}).

ALK mutations
-------------

Although ALK expression was seen in 103 samples, 2 samples did not have sufficient DNA and 101 CRC samples were analysed for ALK mutations. One heterozygous missense mutation was detected in the *ALK* gene among the 101 CRC samples that showed ALK expression. This mutation at base 3421, a G\>A substitution, was seen in exon 21 and located in the tyrosine kinase domain region. This resulted in an amino-acid change from an aspartic acid to an asparagine residue at codon 1141 ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). This is a novel mutation and we further investigated whether this was a somatic or a germline mutation. DNA from corresponding normal colon from this patient was again analysed for the presence of this mutation. Presence of the same novel mutation in the normal tissue confirmed that this mutation is a germline mutation. Although germline mutations of *ALK* gene have been previously identified in familial neuroblastoma, family history was negative in this CRC patient. This patient with an activating germline mutation was a male patient with a Stage II, moderately differentiated adenocarcinoma on the left side with a negative family history, and showed ALK expression that was both cytoplasmic and membranous. However, there was lack of *ALK* gene amplification or gain in copy number.

*KRAS* and *BRAF* gene mutation analysis
----------------------------------------

Analysis of the common altered known gene mutations in CRC were analysed and we studied their correlations with *ALK* gene alteration. A total of 717 of the CRC samples included in this study had been analysed for KRAS and BRAF mutations. We found BRAF mutations in only 17 out of 717 (2.3%) CRC samples, whereas KRAS mutation was found in 201 out of 717 CRC samples (28.0%). Microsatellite instability analysis data was available in 741 samples, and the incidence of MSI-H, microsatellite low and microsatellite stable was 11.2% (83 out of 741), 18.6% (138 out of 741) and 70.2% (520 out of 741), respectively. A mutual exclusivity was observed between KRAS and BRAF mutations (*P*=0.0183). No correlation was observed between present *ALK* gene alteration and known oncogenic mutations in *KRAS* and *BRAF* genes or MSI status in CRC.

*ALK* gene alteration and overall survival
------------------------------------------

The prognostic significance of *ALK* gene amplification and ALK protein expression was analysed using the Kaplan--Meier method. The results showed that the prognosis was poor (*P*=0.0135) in patients with *ALK* gene amplification and gain in copy number as compared with CRC with normal *ALK* gene copy number ([Figure 3A](#fig3){ref-type="fig"}). In the multivariate analysis using the Cox proportional hazard model ([Table 3](#tbl3){ref-type="table"}) for multiple factors such as age, gender, AJCC stage, MSI and tumour differentiation, the relative risk was 2.61 (for *ALK* gene amplification and gain in copy number (95% CI 1.28--4.76; *P*=0.0107) and 6.33 for advanced AJCC stage (95% CI 4.57--8.72; *P*\<0.0001). Thus, *ALK* gene amplification and gain in copy number was an independent prognostic marker for poor survival in CRC across all stages. We also assessed the overall survival of ALK-amplified/gain tumours in advanced Stage IV subgroup only. In Stage IV, CRC with ALK amplification/gain had a poor overall survival of only 3 months as compared with 27 months in CRC with normal copy number of *ALK* gene (*P*=0.0097).

Discussion
==========

Recent reports have shown that ALK tyrosine kinase receptor is a strong biomarker and a good therapeutic target for a significant number of cancer patients ([@bib33]; [@bib24]). Because receptor tyrosine kinases may be activated in human malignancies by genomic amplification, chromosome translocation or point mutations ([@bib10]), we sought to comprehensively analyse *ALK* gene alteration in a large series of CRC. The goal of the present study was to identify the frequency and nature of ALK alterations and to determine whether there was a relationship between these alterations and clinico-pathological findings including clinical outcome. This was accomplished by screening 770 CRC patients treated at KFSHRC and Security Forces Hospital.

We identified increased *ALK* gene copy number (amplification/gain) in 26 out of 756 CRC samples, representing 3.4% of all CRC samples studied, suggesting that ALK copy number increase characterise a small proportion of Saudi Arabian CRC. Furthermore, if we limit our analysis to advanced stage of CRC (Stage IV), ALK amplification showed significant association with poor differentiation, which is indicative of aggressive phenotype. Interestingly, patients harbouring ALK-increased copy number had a significant poor clinical outcome across all stages and also in advanced Stage IV subgroup only. Remarkably, this clinical outcome association was independent of age, gender, tumour stage, grade, histological subtype and MSI status in all CRC cases, thereby confirming that *ALK* gene amplification/gain is an independent prognostic marker for poor survival in CRC.

Screening all colorectal carcinomas for the alterations in *ALK* gene copy number would not be practical owing to the low frequency of ALK amplifications/gain observed. It may be more feasible to screen only the advanced clinical stage CRC to detect ALK amplifications that would benefit from the addition of ALK inhibitor. In contrast to earlier studies in which an excellent correlation was observed between ALK translocations and ALK expression, in colorectal carcinoma, increased *ALK* gene copy number does not translate to increased ALK protein expression, thereby resulting in poor correlation between ALK FISH and ALK IHC. At present, we do not fully understand this mechanism but propose possible mechanisms such as post-transcriptional silencing ([@bib3]; [@bib20]) cancer subtype and site-specific effects modulating ALK expression and other upstream regulator of ALK that could be having a role in this mechanism ([@bib47]; [@bib45]; [@bib57]). A similar lack of correlation has been reported in oesophageal cancer and pulmonary sarcomatoid carcinoma ([@bib49]; [@bib52]).

Existing techniques in the detection of ALK IHC protein and *ALK* gene copy number alterations need to be refined as is evident from the elegant work done by [@bib44] who developed a dual bright-field assay for concurrent detection of ALK protein expression and *ALK* gene rearrangement with much more sensitivity. Given the relative advantages and disadvantages of current ALK IHC and ALK FISH assays, testing of both types might be required for accurate ALK status evaluation in tumours. Recently, [@bib56] have reported ALK inhibitor crizotinib to be responsive in a NSCL patient that was negative for *ALK* gene rearrangement but was positive for ALK expression by IHC . The possibility that crizotinib affected the MET or ROS1 pathways leading to responsiveness was ruled out by investigation of these genes and demonstrating lack of any aberrations ([@bib56]). Considering these important findings, Stage IV CRC with ALK expression alone without *ALK* gene amplification also may benefit from treatment with ALK inhibitors in future clinical trials.

C2orf44-ALK and EML4-ALK fusion (a novel variant novel variant E21;20) have been reported earlier in 2.5% (1 out of 40) and 2.4% (2 out of 83) CRCs, respectively ([@bib39]; [@bib40]). In this study, concurrent rearrangement of ALK/EML4 by FISH was negative, and we did not test for the rearrangement of other fusion partners to ALK such as C2orf44 ([@bib40]), KIF5B ([@bib58]), NPM1 ([@bib43]), VCL ([@bib18]) TFG ([@bib27]), RET ([@bib60]), ROS ([@bib60]), VCL ([@bib18]) and TFG ([@bib27]). Therefore, a concurrent alteration of these loci cannot be excluded. To investigate the role of *ALK* gene alterations other than structural rearrangements in colorectal carcinogenesis, we analysed 101 CRC samples for ALK mutations having ALK overexpression. Only one patient was found to have single-nucleotide heterozygous missense mutation at base 3421; a G\>A substitution was seen in exon 21 and located in the tyrosine kinase domain region. The absence of ALK rearrangement together with the very low percentage of activating mutation in the ALK suggest that these alterations might not be relevant events in CRC.

In conclusion, ALK amplification and copy number gain is an important genetic change in CRC and is associated with poor patient outcome. The findings of our study highlight a potential role of targeting ALK in advanced CRCs by using ALK FISH and ALK IHC as a screening tool to detect ALK alterations. However, these findings need to be validated in future studies in which ALK alterations can be used to identify CRC subsets that can maximally benefit from ALK inhibitors.
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![**Tissue microarray based immunohistochemical analysis of ALK in CRC patients.** An IHC H score was assigned to each case according to the following criteria: 3+, intense, cytoplasmic and/or granular staining; 2+, moderate, smooth cytoplasmic staining; 1+, faint cytoplasmic staining; and 0, no staining and the proportion of the tumour staining for that intensity was recorded as 5% increments from a range of 0--100. (**A**) CRC array spot showing ALK overexpression with membranous staining. (**B**) A CRC array spot showing ALK overexpression with strong, granular cytoplasmic staining (3+). (**C**) A CRC array spot showing ALK overexpression with moderate cytoplasmic staining(2+). (**D**) A CRC array spot showing low cytoplasmic expression of ALK (1+). (**E**) Colorectal cancer tissue array spots with no cytoplasmic expression of ALK (0). (**F**) Normal colon tissue array spots showing no expression of ALK (0). All figures had × 10 magnified image captured with an Aperio ScanScope XT (Aperio Technologies, Vista, CA, USA; objective insets: magnified view × 40 magnified image).](bjc2013641f1){#fig1}

![**Determination of *ALK* gene copy number by flourescence *in situ* hybridization (FISH) and qPCR in ALK-amplified and ALK-non-amplified CRC samples.** A minimum of 20 cells with both the centromeric and *ALK* gene signals were scored to give conclusive data. (**A**) Colorectal cancer ALK-amplified sample hybridised with ALK break-apart probe showing six red and green fused signals (inset showing a single cell with amplification). (**B**) Colorectal cancer ALK-non-amplified sample hybridised with ALK break-apart probe showing normal tissue with two red and green fused signals (inset showing a single cell). (**C**) Colorectal cancer ALK-amplified sample hybridised with BAC probe RP11--328L16 and CEP2 probe showing two red CEP2 signals and 5--6 green signals representing the *ALK* gene amplification (inset showing a single cell with amplification). (**D**) Colorectal cancer ALK-non-amplified sample hybridised with BAC probe RP11--328L16 and CEP2 probe showing two red CEP2 signals and two green signals representing normal ALK copy number (inset showing a single cell). ( × 20/0.70 objective on an Olympus BX 51 microscope (Olympus America Inc, Center Valley, PA, USA) with the inset showing a × 40/0.85 aperture magnified view of the same for [Figure 1A--C](#fig1){ref-type="fig"}). (**E**) Verification of the *ALK* gene copy number by qRTPCR. Histogram showing *ALK* gene copy number obtained from normal colon samples1--4 with two normal copies of *ALK* gene, and samples 5--8 are amplified colon cancer samples.](bjc2013641f2){#fig2}

![**Prognostic significance of ALK in CRC and the Kaplan--Meier survival analysis.** (**A**) Colorectal cancer patients with FISH amplification/gain and increased copy number had reduced overall survival of 53.5% at 5 years compared with 70.9% with normal FISH (*P*= 0.0135). (**B**) In stage IV CRC, patients with FISH gain/amplification and increased copy number had reduced median overall survival of 3 months as compared with a median survival of 27 months with normal FISH (*P*= 0.0097).](bjc2013641f3){#fig3}

###### Clinico-pathological variables for the patient cohort (*n*=770)

  --------------------------------- ------------
  **Age**                           
  Median                            57.0
  Range (IQR)                       47.7--68.0
  **Gender**                        
  Male                              401 (52.0)
  Female                            369 (48.0)
  **Status**                        
  Alive                             574 (74.5)
  Dead                              179 (23.2)
  Unknown                           17 (2.2)
  **Histological type**             
  Adenocarcinoma                    685 (88.9)
  Mucinous carcinoma                85 (11.1)
  **Histological grade**            
  Well differentiated               75 (9.7)
  Moderately differentiated         601 (78.1)
  Poorly differentiated             94 (12.2)
  **Tumour site**                   
  Left                              612 (79.5)
  Right                             123 (16.0)
  Unknown                           35 (4.5)
  **AJCC stage**                    
  I                                 89 (12.2)
  II                                257 (35.3)
  III                               292 (40.1)
  IV                                90 (12.4)
  Unknown                           42 (5.5)
  **Survival duration in months**   
  Median                            35.0
  Range (IQR)^a^                    15--60
  --------------------------------- ------------

Abbreviations: AJCC=American Joint Committee on Cancer; IQR=interquartile range.

###### Correlation of *ALK* (FISH) gene amplification and gain in copy number with clinico-pathological parameters in colorectal carcinoma

                                                    **Total**   **ALK-amplified+gain**   **ALK normal**   ***P*****-value**               
  ------------------------------------------------ ----------- ------------------------ ---------------- ------------------- ----- ------ --------
  **Total number of cases**                            756                                     26                3.5          730   96.5      
  **Age**                                                                                                                                 
  \<50 years                                           218               28.8                  6                 2.7          212   97.3   0.5003
  \>50 years                                           538               71.2                  20                3.7          518   96.3      
  **Sex**                                                                                                                                 
  Male                                                 393               52.0                  13                3.3          380   96.7   0.8368
  Female                                               363               48.0                  13                3.6          350   96.4      
  **Tumour site**[a](#t2-fn3){ref-type="fn"}                                                                                              
  Left colon                                           599               83.1                  22                3.7          577   96.3   0.4859
  Right colon                                          122               16.9                  3                 2.5          119   97.5      
  **Histological type**                                                                                                                   
  Adenocarcinoma                                       673               89.0                  25                3.7          648   96.3   0.1792
  Mucinous carcinoma                                   83                11.0                  1                 1.2          82    98.8      
  **Tumour stage**[a](#t2-fn3){ref-type="fn"}                                                                                             
  I                                                    89                12.5                  4                 4.5          85    95.5   0.7904
  II                                                   250               35.0                  9                 3.6          241   96.4      
  III                                                  281               39.4                  7                 2.5          274   97.5      
  IV                                                   94                13.2                  3                 3.2          91    96.8      
  **Differentiation**[a](#t2-fn3){ref-type="fn"}                                                                                          
  Well/moderate                                        656               87.6                  21                3.2          635   96.8   0.3142
  Poor                                                 93                12.4                  5                 5.4          88    94.6      
  **ALK IHC**[a](#t2-fn3){ref-type="fn"}                                                                                                  
  High                                                 100               14.3                  4                 4.0          96    96.0   0.8130
  Low                                                  597               85.7                  21                3.5          576   96.5      
  **P53 mutation**[a](#t2-fn3){ref-type="fn"}                                                                                             
  Positive                                             181               31.3                  5                 2.8          176   97.2   0.7397
  Negative                                             397               68.7                  13                3.3          384   96.7      
  **Braf mutation**[a](#t2-fn3){ref-type="fn"}                                                                                            
  Positive                                             17                2.4                   1                 5.9          16    94.1   0.6024
  Negative                                             689               97.6                  23                3.3          666   96.7      
  **Kras mutation**[a](#t2-fn3){ref-type="fn"}                                                                                            
  Positive                                             198               28.0                  6                 3.0          192   97.0   0.7325
  Negative                                             508               72.0                  18                3.5          490   96.5      
  **MSI-molecular**[a](#t2-fn3){ref-type="fn"}                                                                                            
  MSI-H                                                83                11.4                  5                 6.0          78    94.0   0.2086
  MSI-S/L                                              642               88.6                  20                3.1          622   96.9      
  **Overall survival**                                                                                                                    
  5 Years                                              ---               ---                  ---               53.5          ---   70.9   0.0135

Abbreviations: ALK=anaplastic lymphoma kinase; FISH=fluorescence *in situ* hybridization; IHC=immunohistochemistry; MSI=microsatellite instability.

Note: missing data were excluded from analysis.

Data were not available (NA) for some cases for tumour site (NA=35), Stage (NA=42), Differentiation (NA=7), ALK IHC (NA=59), P53 mutation (NA=178), Braf mutation (NA=50), Kras mutation (NA=50) and MSI-molecular (NA=31).

###### *ALK* gene amplification: Cox regression analysis for overall survival of patients with colorectal carcinoma

                     **Univariate**     **Multivariate**                      
  ---------------- ------------------- ------------------ ------------------- ----------
  **Age**                                                                     
  Above 50          1.11 (0.80--1.58)        0.5273        0.97 (0.69--1.38)    0.8608
  **Sex**                                                                     
  Male              1.12 (0.82--1.53)        0.4645        1.21 (0.89--1.65)    0.2241
  **Stage**                                                                   
  IV                4.23 (2.98--5.91)       \<0.0001       6.33 (4.57--8.72)   \<0.0001
  **Grade**                                                                   
  Poor              1.55 (1.01--2.28)        0.0426        1.70 (1.10--2.52)    0.0175
  **MSI status**                                                              
  MSI-H             1.34 (0.80--2.44)        0.2749        1.64 (0.99--2.91)    0.0559
  **ALK FISH**                                                                
  Amplified/gain    2.12 (1.08--3.72)        0.0303        2.61 (1.28--4.76)    0.0107

Abbreviations: ALK=anaplastic lymphoma kinase; FISH=fluorescence *in situ* hybridization; MSI=microsatellite instability.

[^1]: These authors contributed equally to this paper.
